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Abstract
Background: The pIVEX plasmids are vectors optimized for expression in the Rapid Translation
System (RTS) cell-free system under control of bacteriophage T7 transcription elements. Even if
these plasmids are intended for use in vitro, it is usually worthwhile to compare both cell-free and
bacterial expression from the same genetic construct. However, some RTS users encountered
problems when they introcuded these plasmids into Escherichia coli host strains producing the T7
RNA polymerase.
Results: We verified that difficulties in transforming the commonly used BL21(λ DE3) strain with
pIVEX arose from the presence of a strong T7 promoter combined with a high-copy number
plasmid, independent of gene expression. When these vectors were introduced into this strain
harboring a compatible plasmid carrying the lactose repressor (lacI), we improved the
transformation efficiency by 4 orders of magnitude. Moreover, we designed a transformation
protocol that allows, after induction, the overproduction of pIVEX-encoded proteins in the
BL21(λ DE3) strain.
Conclusion:  Using the correct plasmid/host combination and transformation-expression
protocol, we could directly compare overproduction of the same pIVEX-encoded proteins from
both in vivo and in vitro expression systems.
Background
Recent developments in cell-free systems offer new and
promising possibilities for producing recombinant pro-
teins [1]. The RTS, commercialized by Roche, is an
exchange cell-free system with improved productivity [2].
The continuous supply of consumable substrates and
removal of reaction products provide a yield of several
milligrams of protein. This system uses bacteriophage T7
RNA polymerase to perform transcription, while an
enriched  E. coli S30 extract provides the translational
machinery. Thus, protein production in RTS requires a
preliminary cloning step of the target gene into a vector,
downstream of the T7 promoter. For this purpose, the
pIVEX family of expression plasmids has been optimized
for in vitro use. They include a T7 promoter comprising the
T7 gene 10 translation enhancer [3], an efficient prokary-
otic Shine-Dalgarno sequence with an optimum distance
to the start codon, a multiple cloning site, and a T7 termi-
nator which prevents 3'-terminal exonucleolytic degrada-
tion of the mRNA. These vectors are very convenient since
multiple cloning sites were designed to allow gene fusions
with several tags either at the N- or C-terminal of target
proteins by conserving the same restriction strategy and
reading frame compatibility.
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Some investigations revealed that less than optimal
expression in this cell-free system could be explained by
the presence of stable secondary structures in mRNAs [4].
Indeed, transcription levels are kept very high due to the
highly active T7 RNA polymerase. Consequently, no real
coupling of transcription and translation can take place in
vitro, and unprotected mRNAs may form stable secondary
structures, notably in the translation initiation region that
inhibit ribosome binding and limit expression levels.
There are mRNA folding algorithms that can predict such
unfavourable intramolecular secondary structures, but
they do not give information about expression levels.
Although similar regulatory mechanisms exist in E. coli
[5], it is simple and useful to assess in vivo expression lev-
els from a pIVEX plasmid which gave poor protein yields
in vitro. The influence of mRNA secondary structures on
translation is not identical in both contexts. However,
transformation of the most widely used T7 RNA polymer-
ase-producing BL21(λ DE3) strain [6] by pIVEX is
impaired because the absence of the lacI gene, coding the
lactose repressor, in these high copy number plasmids.
Here, we report how to solve this problem by designing a
simple protocol with a compatible plasmid carrying the
lactose repressor gene. This method allows the direct com-
parison of in vitro and bacterial expression from pIVEX
vectors.
Results and Discussion
Unlike other T7 promoter-based vectors, the pIVEX do not
contain a lac operator sequence downstream of the T7
promoter. Since expression from pIVEX is not repressed
by LacI, they do not contain the corresponding gene. In
fact, first attempts to transform, by a standard chemical
procedure, the BL21(λ DE3) strain with different pIVEX
failed since no transformant was obtained on LB ampicil-
lin-agar plates. On the assumption that basal expression
from pIVEX may have adverse effects on bacterial growth,
we decided to test various plasmid/host combinations in
order to control more tightly transcription both at the
lacUV5 promoter of the T7 RNA polymerase gene in the
host chromosome, and consequently at the T7 promoter
in the pIVEX plasmid. Furthermore, other investigations
indicated that the transformation efficiency of this E. coli
B strain could be critical [7]. Therefore, we electroporated
freshly BL21(λ DE3) competent cells containing either the
pLysS plasmid encoding T7 lysozyme [8], a natural inhib-
itor of T7 RNA polymerase, or the pDIA17 plasmid [9]
harboring the lacI gene. Both resident plasmids are chlo-
ramphenicol resistant and compatible with pIVEX since
they carry the origin of replication from plasmid p15A. To
facilitate the analysis of expression among the recom-
binants, a pIVEX-GFP plasmid encoding the green fluores-
cence protein, GFP, was used for fluorescence screening of
single colonies on agar plates. As a control for toxic
expression, the same strains were also transformed with
an empty pIVEX plasmid (pIVEX2.4d).
The results presented in Table 1 show that 1) the presence
of the cloned gene coding GFP into pIVEX has no influ-
ence on transformation efficiency, 2) pLysS did not
increase the tolerance of BL21(λ DE3) for either of the
pIVEX plasmids employed, and 3) in contrast, pDIA17
increases the transformation efficiency by 4 orders of mag-
nitude. These results suggest that the basal production of
T7 RNA polymerase in BL21(λ DE3) was incompatible
with a high-copy number plasmid which does not encode
the lacI gene, even without a cloned gene downstream the
T7 promoter. Yet, a substantial increase in lactose repres-
sor from pDIA17 in BL21(λ DE3) cells is sufficient to per-
mit the presence of pIVEX.
Furthermore, the production of GFP could be directly
assessed from the transformation plates. At 37°C in the
absence of IPTG, GFP production from pIVEX-GFP, after
overnight cell growth on solid LB medium, was sufficient
to give fluorescent colonies under these conditions. These
Table 1: Transformation efficiencies of pIVEX vectors into BL21(DE3) strain
Resident plasmid (p15A derivative) Incoming plasmid (pIVEX vector) Transformation efficiency 
(transformants per µg of DNA)a
Colony fluorescenceb
none pIVEX2.4d 3.1 × 104 ± 0.8 -
none pIVEX-GFP 3.5 × 104 ± 0.6 85 % F
15 % NF
pLysS pIVEX2.4d 4.5 × 104 ± 0.8 -
pLysS pIVEX-GFP 4.6 × 104 ± 0.7 90 % F
10 % NF
pDIA17 pIVEX2.4d 7.5 × 108 ± 1.5 -
pDIA17 pIVEX-GFP 8.2 × 108 ± 2.5 100 % F
a Results are mean of three experiments ± SD on LB plates containing antibiotics.
b Transformation plates containing 100 to 200 colonies were observed under UV illumination, NF; non-fluorescent, F; fluorescentMicrobial Cell Factories 2005, 4:18 http://www.microbialcellfactories.com/content/4/1/18
Page 3 of 5
(page number not for citation purposes)
high levels of leaky expression is puzzling, but it has been
shown that when uninduced BL21(λ DE3) cells are grown
to stationary phase in LB medium lacking glucose, the
lacUV5 promoter is derepressed [10]. Apparently, LacI lev-
els from pDIA17 are sufficient to increase pIVEX tolerance
in the competent state, but not to ensure stringent repres-
sion in the uninduced stationary state. Examination of
transformation plates revealed that 100 % of colonies
from BL21(λ DE3)/pDIA17 cells were fluorescent, but
only 90 % from those bearing pLysS (Table 1). This result
suggesting that some transformants lacked GFP produc-
tion, is in good agreement with a recent report in which
the highest production level of a recombinant hemo-
globin, from a comparison of both strains, was found in
the BL21(λ DE3)/pDIA17 strain [11]. Although all trans-
formants obtained with pIVEX-GFP in this strain dis-
played bright fluorescence on transformation plates, a
similar lack of GFP production was observed by subcul-
turing repeatedly these cells in liquid LB medium, con-
taining both ampicillin and chloramphenicol. Indeed,
many studies have already reported that poor protein syn-
thesis or complete lack of protein production is a com-
mon and frequent problem when using the T7 promoter
expression system. Production of toxic proteins causing
plasmid instability is the conventional explanation for
this observation [8]. However, a recent investigation has
suggested that the decrease in protein production levels in
the BL21(λ DE3) strain is more attributable to chromo-
somal mutations reducing the level of functional T7 RNA
polymerase than to significant plasmid loss or to muta-
tions arising on the plasmid [12]. Consistent with this
study, isolation of pIVEX-GFP DNA from the subcultured
non-expressing cells and transformation into new compe-
tent BL21(λ DE3)/pDIA17 cells restored GFP production.
To compare both in vitro and in vivo expression, we used
the maltose-binding protein (MalE), the soluble receptor
for the high-affinity transport of maltose of E. coli, as a
model protein [13]. Previously, we showed that some
additional sequences at the N-terminus of this protein
could influence its production level in the RTS cell-free
system [14]. The four used pIVEX plasmids allow protein
fusion with two different peptide-tags, His- and Strep-tag,
either at the N- or C-terminus of MalE [15]. Among these,
one construct (pIV2.2ME) yielded only very low levels of
protein in the cell-free expression system (Figure 1).
Indeed, when the Strep-tag was fused to the N-terminus of
MalE, the corresponding protein was undetectable on
SDS-polyacrylamide gels stained with Coomassie blue.
Since His-tagged MalE at the N-terminus was correctly
produced, we hypothesized that the Strep-tag sequence
rather than the N-terminal position had a negative influ-
ence, probably by forming an unfavorable secondary
structure in the translation initiation region of mRNA,
which hampers protein synthesis. Because this phenome-
non could be minimized inside E. coli cells, we examined
malE  expression in BL21(λ DE3) from the same four
pIVEX plasmids.
To ensure correct cellular protein production, we freshly
transformed BL21(λ DE3) carrying pDIA17 with the vari-
ous plasmids, and instead of selecting transformants on
LB agar plates supplemented with ampicillin and chlo-
ramphenicol, the selection was carried out in liquid LB
medium containing both antibiotics. Next day, the satu-
rated cultures were diluted (1:100) into fresh liquid LB
medium, supplemented only with ampicillin, and incu-
bated at 30°C. We found that processing the whole pop-
ulation of transformants was less tedious than screening
individual colonies for correct expression, and by lower-
ing the growth temperature to 30°C, the copy number of
the pUC plasmid was decreased [16]. Subsequently, cul-
tures were induced during the log phase, and cells were
harvested 1.5 h after adding IPTG. Following lysis, the
steady-state levels of MalE were analyzed by SDS-polyacr-
ylamide gel electrophoresis. As shown in Figure 1, all
pIVEX yielded very large amounts of MalE under these
conditions. Although expression from pIV2.2ME was
lower than from other plasmids, the corresponding pro-
tein was easily detectable on the gel stained by Coomassie
blue. Thus, in contrast to RTS expression, the N-terminus
Strep-tagged MalE is correctly produced in E. coli cells. In
practice, a successfull cellular expression may help to val-
idate a pIVEX plasmid in which the target gene is correctly
introduced between the regulatory elements, but gave no
detectable expression in vitro.
Conclusion
Using a correct plasmid/host combination and a simple
transformation-expression protocol, we could directly
compare the production of the same pIVEX-encoded pro-
teins in two related expression systems, but performed in
vivo and in vitro. With the development of cell-free systems
in structural genomic and functional proteomic pro-
grams, it will be interesting to systematically investigate,
on a large set of proteins, whether expression behaves sim-
ilarly in both environments.
Materials and methods
Bacterial strain and transformation
E. coli B strain BL21(λ DE3) was obtained from Novagen.
Electroporation was performed using an Eppendorf Elec-
troporator 2510. Bacteria were grown in 100 ml LB to A600
of 0.7, chilled on ice, and harvested by centrifugation (10
min, 1000 g at 4°C). The pellet was washed twice with
100 ml ice-cold distilled water, and once with 5 ml ice-
cold 10 % glycerol. The last bacterial pellet was suspended
in a final volume of 500 µl in 10 % glycerol. Aliquots (50
µl) were mixed with 10 ng plasmid DNA in chilled
cuvettes (0.2 cm electrode gap). A simple pulse of 12.5 kV/Microbial Cell Factories 2005, 4:18 http://www.microbialcellfactories.com/content/4/1/18
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cm was applied and 1 ml of SOC was immediately added.
Then, electroporated bacteria were transferred to polypro-
pylene culture tubes and shaken for 1 h at 37°C before
either plating on LB plates containing ampicillin (100 µg/
ml) and chloramphenicol (25 µg/ml), or diluting into liq-
uid LB medium supplemented with both antibiotics.
Plasmids
Plasmid pLysS was obtained from Novagen, and pIVEX-
GFP, encoding the GFP cycle 3 variant [17], was a gener-
ous gift from Cordula Nemetz. Plasmids pIV2.1ME,
pIV2.2ME, pIV2.3ME, and pIV2.4ME, carrying the wild-
type malE gene without signal sequence, under the control
of T7 promoter, were previously constructed [14] by sub-
cloning the same PCR product into the corresponding
pIVEX2.1MCS, pIVEX2.2bNde, pIVEX2.3MCS, and
pIVEX2.4bNde vectors (Roche). Plasmid pDIA17 is a
pACYC184 derivative carrying the lacI gene under the con-
trol of the tetracycline promoter [9].
Protein synthesis reaction
In vitro MalE synthesis was performed in RTS500 E. coli HY
with the RTS ProteoMaster instrument, essentially as
described in the Instruction Manual from Roche. The
coupled transcription/translation reactions, initiated by
adding 15 µg of pIVEX plasmid DNA, were carried out in
1 ml total volume for 20 hours at 30°C. In vivo expression
was performed in BL21(λ DE3) cells bearing pDIA17 plas-
Comparison of MalE overproduction between in vitro and in vivo expression systems Figure 1
Comparison of MalE overproduction between in vitro and in vivo expression systems. RTS500 E. coli HY extracts (A) and 
BL21(DE3)/pDIA17 whole cell lysates were separated on 12% SDS-polyacrylamide gel electrophoresis followed by staining 
with Coomassie blue. Lanes 1, molecular weight marker; lanes 2, pIVEX2.4d; lanes 3, pIV2.1ME; lanes 4, pIV2.2ME; lanes 5, 
pIV2.3ME; lanes 6, pIV2.4ME.
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mid at 30°C in LB medium supplemented with ampicillin
(100 µg/ml). Cultures were induced at an A600 of 0.8 by
addition of IPTG to a final concentration of 500 µM, and
growth was allowed for 1.5 hours after addition of IPTG.
Proteins from both in vitro and in vivo extracts were sepa-
rated by 12% SDS-polyacrylamide gel and stained by
Coomassie blue.
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GFP – green fluorescent protein
IPTG – isopropyl – β -D-galactoside
LB – Luria Bertani
MalE – maltose binding protein
PCR – polymerase chain reaction
RTS – Rapid Translation System
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